Literature DB >> 14716298

Amplification and overexpression of E2F3 in human bladder cancer.

Andrew Feber1, Jeremy Clark, Graham Goodwin, Andrew R Dodson, Paul H Smith, Anne Fletcher, Sandra Edwards, Penny Flohr, Alison Falconer, Toby Roe, Gyula Kovacs, Nening Dennis, Cyril Fisher, Richard Wooster, Robert Huddart, Christopher S Foster, Colin S Cooper.   

Abstract

We demonstrate that, in human bladder cancer, amplification of the E2F3 gene, located at 6p22, is associated with overexpression of its encoded mRNA transcripts and high levels of expression of E2F3 protein. Immunohistochemical analyses of E2F3 protein levels have established that around one-third (33/101) of primary transitional cell carcinomas of the bladder overexpress nuclear E2F3 protein, with the proportion of tumours containing overexpressed nuclear E2F3 increasing with tumour stage and grade. When considered together with the established role of E2F3 in cell cycle progression, these results suggest that the E2F3 gene represents a candidate bladder cancer oncogene that is activated by DNA amplification and overexpression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14716298     DOI: 10.1038/sj.onc.1207274

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  63 in total

Review 1.  Chromosome 6p amplification and cancer progression.

Authors:  Gda C Santos; M Zielenska; M Prasad; J A Squire
Journal:  J Clin Pathol       Date:  2006-06-21       Impact factor: 3.411

2.  Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.

Authors:  C D Hurst; D C Tomlinson; S V Williams; F M Platt; M A Knowles
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

3.  p110 CUX1 cooperates with E2F transcription factors in the transcriptional activation of cell cycle-regulated genes.

Authors:  Mary Truscott; Ryoko Harada; Charles Vadnais; François Robert; Alain Nepveu
Journal:  Mol Cell Biol       Date:  2008-03-17       Impact factor: 4.272

4.  Targeting Rb inactivation in cancers by synthetic lethality.

Authors:  Gabriel M Gordon; Wei Du
Journal:  Am J Cancer Res       Date:  2011-06-30       Impact factor: 6.166

5.  Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression.

Authors:  Lili He; Hua Yang; Yihong Ma; W Jack Pledger; W Douglas Cress; Jin Q Cheng
Journal:  J Biol Chem       Date:  2008-09-07       Impact factor: 5.157

Review 6.  Nanos genes and their role in development and beyond.

Authors:  Evi De Keuckelaere; Paco Hulpiau; Yvan Saeys; Geert Berx; Frans van Roy
Journal:  Cell Mol Life Sci       Date:  2018-02-03       Impact factor: 9.261

Review 7.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

8.  E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity.

Authors:  P S Danielian; L B Friesenhahn; A M Faust; J C West; A M Caron; R T Bronson; J A Lees
Journal:  Oncogene       Date:  2008-07-28       Impact factor: 9.867

Review 9.  p53 and E2f: partners in life and death.

Authors:  Shirley Polager; Doron Ginsberg
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

10.  Evidence that Igf2 down-regulation in postnatal tissues and up-regulation in malignancies is driven by transcription factor E2f3.

Authors:  Julian C Lui; Jeffrey Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.